{
  "id": 1471831,
  "title": "H.C. Wainwright reiterates Alumis stock rating at neutral, $25 target",
  "url": "https://urgent.news/2026/08/17/h-c-wainwright-reiterates-alumis-stock-rating-at-neutral-25-target",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T11:29:03.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-alumis-stock-rating-at-neutral-25-target-93CH-4862775"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has maintained a Neutral rating and $25.00 price target for Alumis Inc (NASDAQ:ALMS). The stock's current price is $25.31, up 433% over the past year, but down 8% in the last week. Analysts are concerned the stock is overvalued compared to its Fair Value estimate due to clinical trial risks. Alumis is focusing on Sjögren's disease and systemic lupus erythematosus as the next major indications, depending on Q3 2026 LUMUS results and capital allocation. A positive SLE result would support the development of TYK2 inhibition for Type I interferon-driven diseases and justify follow-on studies, potentially creating a new path beyond psoriasis. However, a weak or mixed result would limit near-term value to psoriasis, where an NDA filing and ONWARD3 durability would bolster an approval case but fail to resolve concerns over a 40mg twice-daily dosing profile versus once-daily oral competitors and less frequent dosed IL-23-targeted biologics. H.C. Wainwright will monitor the magnitude and consistency of LUMUS effects, safety, and potential for pivotal path investment in Sjögren's and CLE. The psoriasis filing is seen as an execution milestone, while LUMUS has greater potential to move the stock by adding a second disease pathway. SLE has historically been a clinical development graveyard; thus, H.C. Wainwright awaits LUMUS results to determine if envudeucitinib can overcome this trend and establish TYK2 as a credible therapeutic approach in the disease. The stock has a consensus Buy rating among Wall Street analysts, with price targets ranging from $25 to $55, mirroring differing opinions on the company's clinical prospects. Alumis Inc has been attracting analyst attention as it approaches a significant clinical trial milestone, with Stifel reaffirming its Buy rating at $44.00 and Cantor Fitzgerald maintaining an Overweight rating based on discussions with management about the upcoming Phase 2b readout. These developments underscore the importance of the upcoming clinical trial results for Alumis Inc.",
  "summary": null,
  "key_points": [
    "H.C. Wainwright maintains Neutral rating for Alumis Inc (ALMS)",
    "Stock price $25.31, up 433% year-over-year but down 8% last week",
    "Focus on Sjögren's disease and systemic lupus erythematosus indications"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "H.C. Wainwright reiterates Celcuity stock rating on pricing update",
        "url": "https://urgent.news/2026/08/17/h-c-wainwright-reiterates-celcuity-stock-rating-on-pricing-update",
        "published": "2026-08-17T11:28:53.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}